ESCMID guideline: diagnosis and treatment of acute bacterial meningitisDiederik van de Beek, Matthijs C. Brouwer, Carmen Cabellos et al.|Clinical Microbiology and Infection|2016Cited by 899
Potentially modifiable factors contributing to sepsis-associated encephalopathyRomain Sonneville, Jean‐François Timsit, Étienne de Montmollin et al.|Intensive Care Medicine|2017Cited by 327
Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapyChristophe Adrie, Hakim Haouache, Maïté Garrouste-Orgeas et al.|Journal of Infection|2016Cited by 167
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143
Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimenÉtienne de Montmollin, Romain Sonneville, Lila Bouadma et al.|Intensive Care Medicine|2014Cited by 112